Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03764852

AMBULAPSE STUDY Feasibility Study on Laparoscopic Double-mesh Sacrocolpopexy With or Without Robotic Assistance, in Female Patients Presenting With Symptomatic Pelvic Organ Prolapse, Based on an Outpatient Treatment Model.

Pelvic organ prolapse is an increasingly common functional disorder which affects approximately 30 to 40% of the female population, 12% of whom have a symptomatic form, with a psychological, physical and social impact. Laparoscopic sacrocolpopexy represents the surgical "gold standard" for the treatment of this functional disorder. It aims to suspend the vaginal vault by means of a prosthesis. The patient satisfaction rate is evaluated at 94% with low overall complication rate, evaluated at 11%.

Pelvic organ prolapse surgery is a common, with an estimated 30,000 procedures carried out in France in 2013 (excluding hysterectomy) (2013 ATIH data), and the number will increase in the future due to increasing life expectancy. 13% of women will undergo this type of procedure. The French General Directorate of Health Care Supply (DGOS) deems outpatient surgery to be the benchmark for surgical activity in all eligible patients, and has expressed the need for recommendations and tools for supporting its development. The rate of outpatient surgery for prolapse remains low in France (6.1%, 2015 ATIH data), while it is 25% in the US and 56% in Denmark. The average duration of hospital stays for DRG N81.2 (first degree uterine prolapse) in 2015 was 3.43 days. These procedures have been the subject of publications concerning outpatient care and involving low numbers of patients, with the exception of the publication by Sinhal which involved 111 patients.

Recruiting

Interested in participating?

Request Info

Key information

Age range

40 year–80 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Hopital Antoine Beclere - Aphp, Clamart, France

Loading trial locations.

About this study

In our study, the investigators propose to evaluate the success rate for outpatient laparoscopic sacrocolpopexy with or without robotic assistance in screened patients. With this aim in mind, the investigators will conduct a national multicenter prospective study including 80 female patients. Successful outpatient treatment is defined by the absence of conventional inpatient admission with 24H after surgery, the indications for admission being a CHUNG Score < 9, one perioperative complication, postoperative urinary retention requiring reinsertion of a urinary catheter. The outpatient success rate for other surgical techniques such as cholecystectomy or laparoscopic hysterectomy is above 90% in the literature. Envisaging an equivalent rate after laparoscopic sacrocolpopexy, our population size would make it possible to obtain precision +/- 5.3% for estimation of this proportion. The patients are followed up for 1 month with a postoperative visit at 30 days, during which the efficacy of the technique is evaluated using conventional indicators (POP-Q; ICIQ, USP, PFDI-20, PISQ-12, PFIQ-7, etc.). Once completed, this preliminary investigation will make it possible to define a reference value for successful outpatient sacrocolpopexy, which has not yet been published, which may be used as a basis for a larger scale randomized study that would aim to compare the efficacy of outpatient treatment, with conventional inpatient treatment, for efficient patient management

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • woman between 40 and 80 years old
  • Patient with significant prolapse POP-Q ≥ 2
  • BMI <30
  • ASA score ≤ 2
  • sterile ECBU

Exclusion criteria

  • Criteria related to the pathology or the organ:
  • History of pelvic cancer surgery
  • History of prolapse surgery
  • History of pelvic irradiation
  • Laying a concomitant urethral strip
  • Cervico-vaginal smear test not up to date.
  • Patient pregnant or having a desire for pregnancy
  • Criteria related to concomitant treatments:
  • Cefazoline allergy
  • Taking the following medications within 48 hours
  • Plavix®
  • Vitamin K / Low Molecular Weight Healing Heparin
  • Contraindication to ambulatory care for medical reasons
  • Sleep apnea syndrome
  • Cardiopulmonary pathology
  • Psychiatric pathology
  • Hemorrhagic risk
  • Diabetes imbalanced
  • Unbalanced Hypertension

Treatment and study plan

outpatient laparoscopic

Procedure

The intervention is a outpatient laparoscopic sacrocolpopexy with robotic assistance.

Primary outcomes

  1. Successful outpatient treatment

    Time frame: 24 hours after surgery

    Successful outpatient treatment is defined by the absence of conventional inpatient admission with 24H after surgery, the indications for admission being a CHUNG Score < 9, one perioperative complication, postoperative urinary retention requiring reinsertion of a urinary catheter

Secondary outcomes

  1. The percentage of failure of the outpatient

    Time frame: 24 hours after surgery

    The percentage of failure of the outpatient is defined by the number of patients with a CHUNG score <9 in the outpatient department that does not allow the discharge of the patient or her admission to conventional hospitalization.

Study contacts

Contact information is provided by the study sponsor or research team.

Brannwel TIBI, MD

CONTACT

[email protected]

0492037849

Matthieu DURAND, MD

CONTACT

[email protected]

0492037849

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Nice

Other

Registry information

Official study title

Feasibility Study on Laparoscopic Double-mesh Sacrocolpopexy With or Without Robotic Assistance, in Female Patients Presenting With Symptomatic Pelvic Organ Prolapse, Based on an Outpatient Treatment Model.

Acronym: AMBULAPSE

Important dates

Study start
2019
Primary completion
2026
Study completion
2026
First posted
Dec 5, 2018
Registry last updated
Dec 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.